Compare CVS Health Corp (CVS) vs Wynn Resorts, Limited (WYNN) Price & Performance

CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.

CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.

Wynn Resorts (WYNN) trades at $74.97, down 2.15% today, with a bearish technical signal despite bullish oscillators. The company reported mixed Q2 2026 results, beating EPS estimates but facing margin pressures. Revenue reached $7.14B in 2025, though net income declined to $327M. Analysts maintain a strong buy consensus with a $132.36 price target, while institutional activity shows mixed positioning amid high debt levels and significant capital expenditure plans.

The outlook for WYNN hinges on Macau recovery and successful execution of UAE expansion, but rising capex and debt servicing costs pose risks. Current valuation metrics appear reasonable with P/E of 18.06 and EV/EBITDA of 9.23, though investors should monitor margin trends and project timelines closely given the stock's significant discount to analyst targets.